Drugs / VCL-HM01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02030301 | Dec 2013 → Jun 2015 | genital herpes simplex type 2 infectious disorder | Vical | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VCL-HM01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02030301 ↗ |
| Modality | Vaccine | “Plasmid DNA vaccine encoding one HSV-2 protein; formulated with Vaxfectin®” NCT02030301 ↗ |
| Route | Intramuscular | “by intramuscular injection” NCT02030301 ↗ |